Tonya Winders, MBA, CEO and president of the Allergy & Asthma Network, highlights what she is looking forward to at the European Respiratory Society (ERS) International Congress 2021.
Tonya Winders, MBA, CEO and president of the Allergy & Asthma Network, highlights what she is looking forward to at the European Respiratory Society (ERS) International Congress 2021.
Transcript:
What is your session on asthma guidelines going to entail?
So, I'm excited to attend the European Respiratory Society meeting and to participate in this particular session, which highlights the health care system failures for patients that are living with chronic respiratory disease. So, I'll be bringing forth the patient perspective on how current national policies are lacking for so many patients across the world to ensure that they're getting adequate diagnosis, treatment, and management of their chronic respiratory disease.
What other sessions are you looking forward to hearing about?
Well, it's always exciting to be with the world's leaders at the ERS meetings and to hear the latest science when it comes to chronic respiratory disease. So, I'm certainly looking forward to the sessions on asthma and COPD [chronic obstructive pulmonary disease]. I'm very interested in the COVID-19 long haul and how it may be impacting this community specifically. Again, we were seeing that and hearing that directly from the patient community on a daily basis. So, learning what the latest science and thoughts are on COVID-19 long haul and its relationship to asthma and COPD, specifically, is what I'm looking forward to.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More